Navigation Links
Mayo Clinic study shows Parkinson's disease drug might work in cancer patients
Date:3/13/2008

ROCHESTER, Minn. -- A study published in the March 13 online issue of The Journal of Clinical Investigation shows that dopamine, a drug currently used to treat Parkinsons disease and other illnesses, also might work in cancer patients. The study, which was done in mouse and laboratory models, shows that dopamine could possibly prevent new blood vessels from growing and as a result, slow cancer progression.

Dopamine is a neurotransmitter in the brain that regulates movement and affects behavior. In its synthetic form, dopamine is used to treat heart attack victims, Parkinsons disease and pituitary tumors. But it wasnt known until now that dopamine worked by blocking the growth of new blood vessels (a process called angiogenesis).

Researchers now can test this concept in solid tumors where angiogenesis plays a critical role in the growth and progression of these cancers," says Sujit Basu, M.D., Ph.D., a Mayo Clinic scientist who conducted this study with Partha Sarathi Dasgupta, Ph.D., a scientist with the Chittaranjan National Cancer Institute (CNCI) in Calcutta, India.; and, Debanjan Chakroborty, Ph.D., a postdoctoral fellow in biochemistry at Mayo Clinic and CNCI.

Sometimes new drugs may not be the answer. We looked instead at a novel use for an established product and have found very promising results, Dr. Basu says.

The study has not been replicated in humans, but the results are encouraging, he says.

Dr. Basu has been studying the role of dopamine in cancer for years, and was credited with the initial discovery that dopamine can block new blood vessel growth. His current study is based on mouse and laboratory models of sarcoma -- a malignant tumor affecting soft tissues. The research is the first report that dopamine has a role in cancers use of endothelial progenitor cells to provide a supply line of nourishing blood, Dr. Basu says. These cells, a form of stem cells, are released by bone marrow into the blood system in response to the vascular endothelial growth factor-A (VEGF-A), which is a protein that is secreted by oxygen-deprived cancer cells. The endothelial progenitor cells then help form new blood vessels to feed the cancer.

Researchers discovered that dopamine stops the transfer of endothelial progenitor cells from the bone marrow into the circulatory system by binding to a specific receptor on the surface of the progenitor cells. This binding suppresses the activity of matrix metallopeptidase 9 (MMP-9), an enzyme that enables these cells to move out of bone marrow.

In their experiments, they found that treatment with dopamine significantly decreased mobilation of the progenitor cells from the bone marrow, and it also decreased MMP-9 expression.

This is the first time it has been shown that an important neurotransmitter like dopamine is regulating the mobilization of these progenitor cells from the bone marrow. This is very important and represents why these findings are so unique, Dr. Basu says.

Other authors include: Chandrani Sarkar, Ph.D., of both CNCI and Mayo Clinic; Uttio Roy Chowdhury, Ph.D., and Rathindranath Baral, Ph.D., both of CNCI.


'/>"/>

Contact: Amy Reyes
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Radiologists encouraged to look beyond cancer for clinically unseen diseases
3. Clinical depression linked to abnormal emotional brain circuits
4. Preclinical study suggests organ-transplant drug may aid in lupus fight
5. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
6. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
7. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
8. MinuteClinic Becomes Participating Provider with Assurant Health
9. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
10. Acupuncturists Relocation Tightens Relationship With Fertility Clinic
11. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... If you are feeling that your clothes are a tad ... to the Center for Disease Control and Prevention (CDC), 34.9% of U.S. adult women ... of cancer, some of the leading causes of preventable death. February is heart ...
(Date:2/8/2016)... ... 2016 , ... Delta Dental of California and its affiliated companies announced today ... Radine, who recently retired as president and CEO of Delta Dental of California and ... the Year , helped lead the effort to raise funds for studies to strengthen ...
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home show ... to see the most incredible gardens and home improvement experts that attend this amazing ... Center - 700 14th St. Denver CO, is an exciting event that Performance Mobility ...
(Date:2/8/2016)... ... 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated ... his birthday on February 10th. During this time, people can achieve better health, ... 250,000 people from over 40 different countries as an “ordinary man with an extraordinary ...
(Date:2/7/2016)... Dallas, Texas (PRWEB) , ... February 07, 2016 ... ... its new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and ... , MyDecision™ combines three elements to cut the cost of providing employee healthcare ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)...  Avista Pharma Solutions ("Avista Pharma") announced today that ... Officer (CFO). Mr. Setzer is a finance and operations ... roles within growing technology and life science companies. Prior ... Director of Finance at INC Research, a publicly traded ... . Previously, Mr. Setzer served as CFO of Expression ...
(Date:2/8/2016)... 8, 2016 Vestagen Technical Textiles, Inc., a ... for healthcare and other demanding applications, today announced it ... He replaces Dale Pfost , PhD, who was ... is also joining Vestagen,s Board of Directors. ... active barrier technologies that combines fluid repellent, antimicrobial and ...
(Date:2/8/2016)... 8, 2016  Astellas Pharma Inc. President and Chief Executive ... James Robinson as president, Americas Operations, for Astellas ... and South America , effective April 1, ... the commercial organization in the United States ... Masao Yoshida , who is retiring in June 2016.  ...
Breaking Medicine Technology: